United Therapeutics (UTHR) Profit After Tax Growth (3y) (2012 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Profit After Tax Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | 0.97% |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | 39.29% |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | 12.02% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | -28.18% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -34.73% |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 42.23% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 8.71% |
| 10 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn | 15.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.71% |
| Mar 31, 2026 | 4.50% |
| Dec 31, 2025 | 40.23% |
| Sep 30, 2025 | 12.28% |
| Jun 30, 2025 | 38.70% |
| Mar 31, 2025 | 10.33% |
| Dec 31, 2024 | 39.00% |
| Sep 30, 2024 | 23.85% |
| Jun 30, 2024 | 17.23% |
| Mar 31, 2024 | 121.27% |
| Dec 31, 2023 | 30.01% |
| Sep 30, 2023 | 16.05% |
| Jun 30, 2023 | 34.26% |
| Mar 31, 2023 | 20.49% |
| Dec 31, 2022 | 35.93% |
| Sep 30, 2022 | 21.81% |
| Jun 30, 2022 | -17.30% |
| Mar 31, 2022 | 35.45% |
| Dec 31, 2021 | 19.77% |
| Sep 30, 2021 | 15.17% |